Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons

AIDS Research and Human Retroviruses

Volumn 18, Issue 8, 2002, Pages 535-543

  Bartlett, John A ^a   Miralles, G Diego ^b   Sevin, Anne D ^c   Silberman, Martha ^a   Pruitt, Scott K ^a   Ottinger, Janet ^a   Gryszowska, Victoria ^a   Fiscus, Susan A ^d   Bucy, R Pat ^e   Mahon, Laura ^f   Levy, Wende ^f   O’neill, Dorothy ^f   Vargas, Michelle Blanchard ^f   Lehky, Tanya ^g   Adams, Elizabeth ^g   Estep, Scharla ^g   Bancroft, Lynne ^h   Wang, Rui ⁱ   Chan, Ellen ⁱ   Kilgo, Patrick ⁱ   Lilly, Scott G ^a   Petros, William ^a   Colvin, O Michael ^a   Smith, Clayton ^j   Hamzeh, Fayez ^k   Kennedy, Michael ^l   Goodwin, S Diane ^m   Rinehart, Alex ^m   Stevens, Michael ⁿ   Becker, Mark ^o   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Trimeris Pharmaceuticals   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Pediatric ACTG Operations Center   (United States)

^g National Institutes of Health Division of AIDS   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ HARVARD UNIVERSITY   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l Johns Hopkins University ^*  (United States)

^m GLAXOSMITHKLINE   (United States)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o AGOURON PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; LAMIVUDINE; NELFINAVIR; STAVUDINE; VIRUS DNA;

ADULT; ARTICLE; BLOOD LEVEL; CELL COUNT; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPHOCYTE COUNT; LYMPHOID TISSUE; MALE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; LYMPHOID TISSUE; MALE; MIDDLE AGED; MONOCYTES; NELFINAVIR; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE; VIRAL LOAD;

EID: 0036267284     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202753747888     Document Type: Article

References (31)

1. Lymphoid organs function as major reservoirs for human immunodeficiency virus
2. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
3. Molecular basis of latency in pathogenic human viruses
4. Quantitation of latent tissue reservoirs and total body load in HIV-1 infection
5. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
6. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
7. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
8. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
9. Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir
10. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
11. Latent infection of CD41 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
12. Relationship between pre-exisiting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
13. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs
14. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS
15. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin's lymphoma
16. In-vitro effects of 4-hydroxycyclophosphamide on the morphology and function of human peripheral blood mononuclear phagocytic cells (macrophages)
17. The influence of cyclophosphami de on lymph-node and peripheral blood lymphocytes in mice
18. The effect of anti-neoplastic drugs on murine acquired immunodeficiency syndrome
19. Immunosuppressive drug therapy for rheumatic disease
20. Stability in the HIV vDNA pool in peripheral CD41 T cells of untreated patients by using single tube quantitative PCR
21. Combining dependent tests with incomplete repeated measures
22. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
23. Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA
24. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection
25. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
26. Viral dynamics in human immunodeficiency virus type 1 infection
27. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy
28. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
29. Self-reported antiretroviral adherence correlates with HIV viral load and declines over time